Daflon 500M: Main Therapeutic Uses

Daflon 500M is a medicinal product intended for use in adults to address symptoms related to certain circulatory conditions. The active components include micronized purified flavonoid fraction (MPFF), which is a combination of diosmin and hesperidin.

Key Therapeutic Domains

The product is commonly administered for two primary areas of supportive care:

• Chronic Venous Insufficiency (CVI) Symptoms: It is used to help manage the uncomfortable symptoms that accompany chronic venous disorders, particularly those affecting the lower limbs. This includes addressing symptoms such as heaviness, pain, restlessness in the legs, and other discomforts associated with poor vein function. The aim of therapy is to provide symptomatic relief.
• Acute Hemorrhoidal Symptoms: Daflon 500M is also indicated for the short-term supportive management of symptoms related to an acute hemorrhoidal episode. This includes helping to alleviate the associated pain, swelling, and other manifestations of this condition. When managing hemorrhoidal symptoms, this therapy is typically used alongside other recommended treatments.

Consultation with a healthcare professional is necessary to determine if this product is appropriate for an individual’s specific circumstances.

---

Quick Facts: What Daflon 500M Treats

• Addresses: Symptoms of chronic venous insufficiency (CVI).
• Supports: Symptomatic relief for heaviness and restlessness in the legs.
• Manages: Short-term symptoms of acute hemorrhoidal episodes.

Regulatory References

1. EMA therapeutic overview of diosmin-containing medicinal products

Who Can and Cannot Use Daflon 500M

The eligibility criteria for Daflon 500M are defined by regulatory authorities and based on specific population restrictions and contraindications, strictly documented in the official prescribing information.

---

Eligibility Scope

Category	Population Status
Populations for whom use is allowed	Adults
Populations for whom use is not recommended	Pregnant Women (Preferable to avoid as a precautionary measure), Breast-feeding Women (Not recommended), Children and Adolescents under 18 years of age (Safety and efficacy not established)
Populations for whom use is contraindicated	Patients with Hypersensitivity to the active substance (Micronized Purified Flavonoid Fraction) or to any of the excipients

---

Official Eligibility Summary

The medicine is contraindicated for use in individuals who have a known hypersensitivity or allergy to the active components (diosmin and hesperidin) or other tablet ingredients. Use is formally established for the adult population.

The regulatory labeling states that the safety and efficacy of Daflon 500M have not been established in the pediatric population (those under 18 years of age). Furthermore, the medicine is not recommended for breast-feeding women due to unknown excretion into human milk, and it is preferable to avoid use in pregnant women as a precautionary measure due to limited clinical data. Official documentation does not list specific restrictions or contraindications related to renal or hepatic impairment.

Interactions with other medicines and products

Official regulatory information regarding interactions for Daflon 500M (Micronized Purified Flavonoid Fraction or MPFF) is based on the current available clinical and post-marketing data.

The regulatory profile is defined by the official statement that no formal drug interaction studies have been performed specifically with this product's formulation. As a result, the regulatory documentation does not list any mandatory restrictions or prohibited combinations based on a known interaction risk.

---

Official Regulatory Interaction Status

Category	Regulatory Status
Documented Drug-Drug Interactions	None documented.
Metabolic (CYP) or Transporter Interactions	Not documented in the regulatory label.
Contraindicated Combinations	None listed due to interaction risk.
Timing or Separation Requirements	None documented.
Interactions with Food, Alcohol, or Supplements	None documented.

---

The regulatory status is further supported by post-marketing surveillance, which has reported no clinically relevant drug interactions to date with this product. Consequently, the official labeling provides no warnings regarding altered plasma concentrations, clearance reduction, or specific requirements for dose separation when co-administering the product with other medications, foods, or supplements.

Daflon 500M, a micronized purified flavonoid fraction, exerts its pharmacodynamic activity primarily on the microcirculation and venous system. Its mechanism involves modulating the cellular inflammatory cascade within the perivascular space. The compound acts by inhibiting the activation, migration, and adhesion of leukocytes (neutrophils and macrophages) to the endothelial lining. This interaction decreases the release of various inflammatory mediators, including prostaglandins, thromboxane, and free radicals.

At the systemic level, this action decreases capillary hyperpermeability and alters venous tone. Specifically, the compound increases norepinephrine-induced vasoconstriction, thereby reducing venous distensibility and capacitance. This targeted physiological modulation of the venous endothelium and microvasculature constitutes the core mechanism of action.

Administration Guidelines for Daflon 500M

Daflon 500M is an oral medicine supplied as a film-coated tablet. Administration guidelines describe distinct dosing schedules and durations based on the clinical context.

---

Dosing Schedule and Frequency

Usage Context	Daily Dosage	Administration Frequency	Course Duration
Chronic Venolymphatic Symptoms	Two (2) tablets per day (1000 mg MPFF total)	Two divided doses (midday and evening)	Long-term use pattern
Acute Hemorrhoidal Attack	Six (6) tablets per day (3000 mg MPFF)	Divided doses (e.g., three times daily)	First 4 days
Acute Hemorrhoidal Attack	Four (4) tablets per day (2000 mg MPFF)	Divided doses (e.g., twice daily)	Next 3 days

---

Procedural Instructions and Use Context

Standard instructions indicate that the tablets should be taken at meal times (midday and evening is specified for the chronic dose). The tablets must be swallowed whole with water and should not be crushed or chewed.

The regimen for acute hemorrhoidal symptoms is a defined, short-term seven-day course only. For chronic symptom support, the product may be part of a long-term management plan. If a dose is forgotten, the instruction is to not take a double dose to compensate for the missed one; instead, the regimen should continue at the next scheduled time. The safety and efficacy of Daflon 500M have not been established in children and adolescents under 18 years of age.

Research Evidence / Overview of Studies for Daflon 500M

---

Evidence for Use in Chronic Venous Insufficiency (CVI) Symptoms

Research exploring the use of Daflon 500M (MPFF) for chronic venous disease (CVD) primarily consists of Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were conducted to examine how the agent was studied in relation to the peripheral vascular system. Researchers included adults across the entire range of chronic venous insufficiency (CVI), from those with mild discomfort to those with advanced conditions, including active venous leg ulcers.

The research examined measurements of subjective discomfort, such as pain intensity, the feeling of heaviness, and nocturnal cramps, with studies reporting how symptoms evolved in the observed populations. Furthermore, studies explored objective outcomes by monitoring physical changes, such as edema measurements by measuring ankle and calf circumference, with findings contributing to understanding symptom patterns.

---

Evidence for Acute Hemorrhoidal Symptoms

The evidence base for acute hemorrhoidal symptoms is mainly derived from short-term, acute Randomized Controlled Trials (RCTs). This research was relevant in trials assessing short-term or episodic symptom patterns associated with conditions characterized by acute or disruptive episodes. Studies were conducted during periods of increased symptom activity and examined outcomes related to symptoms such as acute pain, bleeding (proctorrhagia), and localized swelling or discomfort.

The studies monitored how outcomes related to physical discomfort changed in the observed populations over defined, very short time intervals. Research also monitored objective local signs, such as a physician's assessment of edema and inflammation. The findings contribute to the broader evidence landscape, providing insight into short-term changes during the acute phase of the condition.

---

Long-term Studies and Follow-up Duration

The follow-up durations for studies involving Daflon 500M were limited in many cases, especially the highly controlled RCTs. Research exploring short-term symptom changes typically lasted between one and three months. The data are still emerging regarding the durability of the observed effects over many years. Therefore, while findings provide insight into short-term changes, the long-term effects are not fully established regarding sustained outcomes or influence on disease progression.

---

Evidence Gaps and Areas of Uncertainty

A review of the evidence highlights several research limitation frames. One key area is that the evidence quality varies across studies, and the variability in measurement scales used to assess symptoms across different trials can make comparison challenging. The long-term effects are not fully established as many studies focus on the acute phase or short-term symptomatic outcomes. Furthermore, comparative evidence is lacking in some areas, particularly large-scale studies comparing MPFF directly against all available treatment options.

Key Studies & References

1. DAFLON 500 mg, film-coated tablets - Summary of Product Characteristics (SmPC)

Common questions about Daflon 500M (FAQ)

Q: What is the difference between Daflon 500M and other common diosmin-based supplements?

Daflon 500M is specifically formulated as a medicine containing a Micronized Purified Flavonoid Fraction (MPFF), which is a blend of diosmin and hesperidin. The key feature is the micronization process, which reduces the size of the active particles. Official product information indicates this reduction is performed to support enhanced absorption of the active components in the body compared to non-micronized forms.

Q: What is the meaning of 'micronized purified flavonoid fraction' in simple terms?

This medical term describes the active ingredients in the tablet, which are Diosmin (450 mg) and Hesperidin (50 mg). The ingredients are purified from natural sources, and the term micronized means the particles have been mechanically reduced in size. This process is used because it is intended to help enhance the absorption of the medicine.

Q: What are the signs of a serious or severe allergic reaction to Daflon 500M?

Signs of a severe allergic reaction can include rapid, localized swelling of the face, eyelids, or lips (called isolated oedema). Rarely, a patient may experience Quincke's oedema (angioneurotic oedema), which involves rapid swelling of the deeper tissues. If signs of rapid swelling occur, immediate medical evaluation is necessary.

Q: How long does it typically take for a patient to notice an improvement in chronic leg symptoms?

Studies examining the use of Daflon 500M for chronic venous symptoms, such as leg pain and heaviness, show that reductions in discomfort levels have been observed. Evidence indicates that symptom improvement has been observed to begin after one month of treatment, with some studies monitoring further improvement after two months of use.

Q: What follow-up is recommended if hemorrhoid symptoms persist after 15 days of using the medicine?

Official regulatory guidance states that if symptoms associated with a hemorrhoidal attack do not disappear within 15 days of treatment, a patient should seek advice from their doctor. This is necessary for a full medical review to evaluate the symptoms further.

Q: Is Daflon 500M classified as a blood thinner or an anticoagulant?

No. Daflon 500M is officially classified as a Venoactive Drug (VAD) or phlebotonic. This classification means its main action is targeted at supporting the function of the veins and microcirculation, and it is not classified as a blood thinner (anticoagulant).

Q: Is Daflon 500M intended to replace non-drug therapies like compression stockings?

Regulatory patient information suggests that the use of the medicine is recommended as part of a healthy lifestyle. For venous circulation disorders, this includes avoiding excessive standing and wearing special support stockings (compression) where applicable, rather than replacing these non-drug measures.

Q: Does Daflon 500M carry a warning about affecting a patient's ability to drive or operate machinery?

Regulatory documentation specifically addresses the ability to drive and use machines. Based on the known safety profile, the medicine is expected to modify this ability only to a negligible extent or not at all.

Q: What caution is advised for patients with existing kidney or liver conditions regarding Daflon 500M?

Official documentation does not list specific restrictions or contraindications related to renal (kidney) or hepatic (liver) impairment. However, consultation with a healthcare professional is generally appropriate for individuals who have existing severe liver or kidney problems.

Q: Why do some product leaflets mention both Daflon 500mg and Daflon 1000mg versions?

The two strengths exist to accommodate different dosing needs. The 1000mg version is an alternative strength that contains a total of 1000 mg of the active ingredient (MPFF). This strength is typically used to achieve a higher total daily dosage as prescribed by a doctor.

Q: Is there any evidence to suggest Daflon 500M causes changes in body weight?

Official regulatory documentation that lists all known and reported adverse events does not list weight change. Therefore, weight change is not considered a known or reported side effect of this medicine.

Q: Can Daflon 500M be used by individuals with a history of stomach or bowel issues?

Official documents do not list a history of stomach or bowel issues as a contraindication for use. However, the most frequently reported side effects of the medicine are related to the gastrointestinal system, including diarrhea, nausea, and abdominal pain.

Q: What precautions related to sun exposure are associated with Daflon 500M use?

Official patient information notes that for venous circulation disorders, a healthy lifestyle includes avoiding exposure to the sun and heat. Excessive heat can exacerbate symptoms associated with poor venous function.

Q: Is Daflon 500M suitable for patients who are managing diabetes?

Official regulatory documents do not list diabetes as a contraindication for use. However, consultation with a doctor before beginning any new medication is appropriate for individuals managing poorly controlled diabetes.

Storage and Disposal Requirements

The storage and disposal of Daflon 500M film-coated tablets must strictly follow the conditions specified in the official regulatory product information to maintain product integrity and ensure environmental safety.

Storage Component	Official Requirement
Temperature	Store below 30 C
Packaging	Store in the original carton
Stability	Do not use after the expiry date stated on the box
Safety	Keep out of the sight and reach of children

For disposal, unused or expired Daflon 500M must not be disposed of via wastewater or household waste. This environmental restriction is mandatory. Users are required to consult a pharmacist for instructions on proper disposal to ensure compliance with local regulations.